Pipeline

We have developed a highly specific and sensitive method to predict the effect of immune checkpoint inhibitors (Nivolumab) by examining lymphocytes in the blood.

The method has several advantages: It does not use cancer tissue, is relatively inexpensive, analyzed quickly and are already used in clinical trials.

Patent No. 6664684
Joint research with Professor Hiroshi Kagami of Saitama Medical University.

The study on a new immune cell (Th7R), CCR4-CCR6 + CD4+ T cells, discovered it is possible to predict the effects of immune checkpoint inhibitors, PD-1 inhibitors or PD-L1 inhibitors, more easily and with higher sensitivity and specificity than ever before using blood.

Patent No. 7175068
Joint research with Professor Hiroshi Kagami of Saitama Medical University.

The measurement of the number of immune cells in the blood was found to be effective in predicting the severity of pneumonia in COVID-19.

Patent pending
Joint research with Professor Hiroshi Kagami of Saitama Medical University.

We are developing a cell therapy based on a novel CD4⁺ T cell subset (Th7R) that plays a key role in sustaining immune responses.

Th7R cells are suggested to maintain long-term antitumor immunity, and their combination with immune checkpoint inhibitors is expected to enhance therapeutic efficacy.

Patent pending
Joint research with Prof. Hiroshi Kagamu, Saitama Medical University